ArticleHuman vaccines & immunotherapeutics2016
The cost of vaccination throughout life: A western European overview.
Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- The impact of coronavirus disease 2019 (COVID-19) pandemic experiences on attitudes towards vaccinations: on the social, cultural and political determinants of preferred vaccination organization models in Poland.Health research policy and systems · 2024Article
- [Updated cost of vaccinating throughout life in Spain in 2023].Revista espanola de salud publica · 2023Article
- Prices of paediatric vaccines in European vaccination programmes.Vaccine: X · 2023Article
- Public health impact and return on investment of Belgium's pediatric immunization program.Frontiers in public health · 2023Article
- Trends in hospitalization and death rates among patients with head and neck cancer in Spain, 2009 to 2019.Human vaccines & immunotherapeutics · 2022Article
- Reducing the infectious diseases burden through "life course approach vaccination" in India-a perspective.AIMS public health · 2021Article
- Towards adult vaccination in India: a narrative literature review.Human vaccines & immunotherapeutics · 2020Review
- [The cost of vaccination throughout life in Spain].Revista espanola de salud publica · 2020Article
- Trends in vaccine investment in middle income countries.Human vaccines & immunotherapeutics · 2019Article
- Vaccination programs for older adults in an era of demographic change.European geriatric medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the interest of policy makers, the actual investment in vaccination is poorly documented. Our study assessed the costs of vaccination throughout life for a fully immunized Western European citizen. National vaccination calendars for England, France, Germany, Italy, Portugal, Spain and Sweden were retrieved. We differentiated men from women and healthy individuals from those suffering from underlying conditions who require specific additional vaccinations. Vaccine costs and administration fees were retrieved from official national source and calculated from the national healthcare perspective. Vaccinating an individual against up to 17 diseases throughout his entire life and in full compliance with national vaccination calendars cost between €328 and €2,352 (vaccines costs only) and between €443 and €3,395 (administration costs included), the lowest range corresponds to a healthy man in Sweden and the highest to a woman with underlying conditions in England. Vaccination costs varied among countries due to heterogeneous national vaccination calendars and organization. In all countries, adults (18-64 y) and elderly (≥65 y) accounted for the lowest vaccines costs compared with infants (0-24 m) and children/adolescents (2-17 y). In comparison, other mass secondary preventive therapies may be at least 3 times more costly. Vaccination requires a relatively low level of investment per individual. Our estimates should be considered to be the maximum potential costs due to our 100% compliance assumption. Increasing coverage rates would bring additional public health benefits for a relatively low incremental cost. A life-course approach of vaccination should also be encouraged because some missed opportunities remain in senior vaccinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.